Cambridge, UK, 18 September 2018 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it was chosen as the winner of the ‘Life Science Spin-out of the Year’ at the recent Biotech and Money 2017 Awards.
The award recognises both Microbiotica’s potential in the microbiome sector and its achievements to date as the newest spin-out company from the world-renowned Wellcome Trust Sanger Institute, including its £8m equity financing in 2016 from Cambridge Innovation Capital and IP Group. The Company is at the forefront of understanding how the microbiome can be used to develop new therapeutics for a range of diseases and to stratify patients according to their microbiata.
Votes for each category were determined 50% by advanced online voting and 50% by a live vote on the night of the Awards dinner, which was held in London on 14 September.
Dr Mike Romanos, CEO of Microbiotica, said: “It is rewarding for our team to achieve this recognition in our first year. Being selected for this award by our peers is a great endorsement of the strength of our science and the commitment of our talented team.”
About Microbiotica
-
Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute.
-
Microbiotica’s founders are Mike Romanos, Trevor Lawley and Gordon Dougan, FRS.
-
CIC and IP Group are co-investors in Microbiotica, with a £4m contribution from each party to provide total initial funding of £8m.
-
Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute.
-
www.microbiotica.com
About the Microbiome
Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
Microbiotica
Rowena Gardner
rgardner@microbiotica.com
+44 1223 786063 / +44 7801 480569 Instinctif Partners (for media enquiries):
Sue Charles/Gemma Harris
microbiotica@instinctif.com
+44 20 7866 7860
Back to news
